This Week in Urology — Aug 28, 2026

Welcome to This Week in Urology. This week we're covering 10 notable papers spanning functional and reconstructive outcomes after prostate cancer treatment, the evolving surgical and pharmacologic management of benign prostatic hyperplasia, and a set of practical questions in uro-oncology and perioperative care. Let's dive in.

We start with the long tail of prostate cancer treatment, because three papers this week deal with what happens to continence, the urethra, and sexual function years after the cancer is treated. The headline is the 24-month report from the MASTER trial in European Urology Focus, a 27-centre United Kingdom randomised noninferiority trial of the transobturator male sling versus the artificial urinary sphincter in 380 men with bothersome urodynamic stress incontinence after prostate surgery [1]. At two years the sling remained formally noninferior to the sphincter for self-reported continence, and symptom scores improved substantially in both arms, falling from around sixteen at baseline to roughly seven or eight. But almost every secondary and post hoc analysis favoured the sphincter, and the difference that will matter in clinic is reoperation: by 24 months, twenty men in the sling group, about one in nine, had undergone further surgery, compared with only four men in the sphincter group. So the honest counselling message is that both operations work and most men are satisfied even when they are not completely dry, but the sling buys simplicity at the cost of a meaningfully higher chance of coming back to theatre. Staying with reconstruction, The Journal of Urology published a two-centre series from Rourke and Gelman of 212 men undergoing posterior urethroplasty for radiation-induced bulbomembranous stenosis, comparing anastomotic repair with buccal mucosal graft onlay [3]. Median stenosis length was two centimetres and median follow-up in men without recurrence was over eight years. Graft onlay was independently associated with roughly a three-fold higher hazard of recurrence, with a ten-year cumulative recurrence risk of about twenty percent versus under seven percent for anastomotic urethroplasty. Importantly, there was no penalty in complications, satisfaction, de novo erectile dysfunction, or incontinence, which were similar between techniques. The practical implication is that in the irradiated posterior urethra, when excision and primary anastomosis is technically feasible, it should probably be the default rather than a fallback.

The third paper in this theme comes from BJU International and quantifies something we counsel about constantly but rarely measure at scale: sexual function after curative treatment [10]. Hess-Busch and colleagues analysed more than thirteen thousand men in the international TrueNTH Global Registry with baseline and twelve-month patient-reported outcomes after radical prostatectomy, external beam radiotherapy with or without androgen deprivation, or brachytherapy. Sexual function declined significantly with every modality. The median fall was steepest after surgery, around sixty percent, and smallest after brachytherapy, around forty percent. At twelve months, poor or absent erectile function was reported by between roughly two thirds and over nine in ten men, worst after prostatectomy and after radiotherapy combined with androgen deprivation. Sexual aid use rose after treatment but stayed low across the board. This is registry data with non-representative sites, so it is associational, but the signal is consistent enough to argue for franker pre-treatment counselling and for building structured sexual rehabilitation into survivorship pathways rather than leaving it to the patient to ask.

Turning to benign prostatic hyperplasia, three papers address terminology, drug safety, and value. In European Urology Focus, Ochoa and colleagues compare how the 2026 European Association of Urology guideline on non-neurogenic male lower urinary tract symptoms and the 2026 American Urological Association guideline on symptoms attributed to benign prostatic hyperplasia align with International Continence Society terminology [2]. It sounds administrative, but the point is clinically real: when guidelines use different words for the same symptom complex, comparing trials and auditing our own outcomes becomes harder. Then in Urology, Titus and colleagues used the TriNetX network to compare over half a million men on 5-alpha reductase inhibitors with a propensity-matched non-user cohort, followed for a median of about three years [6]. Reassuringly, there was no increased risk of male breast cancer overall, and none for finasteride or dutasteride separately. There was, however, a clear increase in gynaecomastia, roughly a fifty percent relative increase, and a small but consistent increase in erectile dysfunction of around fifteen to twenty percent. Both signals were stronger for dutasteride, where gynaecomastia risk was roughly doubled. That is a useful, specific consent conversation: breast cancer fear can be largely put to rest; breast tenderness, enlargement, and sexual side effects cannot. Also in Urology, Wymer and colleagues built a microsimulation cost-effectiveness model of all guideline-supported surgical options, from a United States Medicare payer perspective, stratified by prostate size [7]. For glands between thirty and eighty cubic centimetres, holmium laser enucleation produced the most quality-adjusted life years, at a cost of about eight thousand four hundred dollars per patient, well below prostatic artery embolisation at just over sixteen thousand. For large glands between eighty and one hundred fifty cubic centimetres, enucleation matched simple prostatectomy for effectiveness at less than half the cost. The crucial caveat the authors emphasise is that these rankings flip depending on how much an individual man weights ejaculatory preservation versus maximal symptom relief, so this is an argument for enucleation capacity in the system, not for abandoning shared decision-making.

Our third theme groups two oncology papers and two questions of everyday practice. In The Journal of Urology, Joffe and colleagues report on 61 patients with muscle-invasive bladder cancer who achieved clinical complete response after cisplatin-based neoadjuvant chemotherapy and entered a strict bladder-sparing surveillance protocol [4]. Over a median follow-up of about 28 months, 28 patients had a non-muscle-invasive recurrence, and four out of five of those recurrences were high grade, most managed with induction BCG. Critically, having a non-muscle-invasive recurrence was not associated with later muscle-invasive recurrence or metastasis. So for the patient unfit for or refusing cystectomy, recurrence during surveillance is common but usually salvageable endoscopically, provided the surveillance is genuinely rigorous. On the staging side, Prostate Cancer and Prostatic Diseases reports on 544 intermediate and high-risk men who had PSMA PET/CT before radical prostatectomy [9]. An intraprostatic maximum standardised uptake value at or above the median of 9.5 independently predicted non-organ-confined disease and adverse pathology, and was associated with worse biochemical recurrence-free survival at four years, about 62 percent versus 72 percent. That suggests the intensity of intraprostatic uptake, not just its presence, carries prognostic information worth reading off the scan you already ordered.

Two practical papers round things out. In Urology, Nguyen and colleagues analysed nearly 280,000 patients undergoing radical prostatectomy, nephrectomy, or transurethral resection of bladder tumour, and found that an abnormal preoperative urinalysis predicted postoperative urinary tract infection, sepsis, and bacteraemia more consistently than an isolated positive culture did [5]. Strikingly, among patients with an abnormal urinalysis, only about one in twenty prostatectomy patients and one in ten bladder tumour patients also had a positive culture, and adding that positive culture provided limited extra prognostic information. The authors are careful not to recommend abandoning culture where clinically indicated, but this supports testing selective, urinalysis-guided reflex culture strategies prospectively. And in World Journal of Urology, Lim and colleagues meta-analysed six retrospective cohorts, 511 patients, comparing metallic with polymeric stents for chronic malignant ureteric obstruction [8]. Metallic stents showed only a non-significant trend toward lower stent failure, with comparable symptoms and complications; the narrative advantage was fewer exchanges. The authors explicitly call this not practice-changing.

If you only have time for one paper this week, make it the MASTER 24-month report in European Urology Focus [1]. It is the largest randomised comparison we have for male stress incontinence surgery, and the gap between a technically noninferior primary outcome and a five-fold higher reoperation rate is exactly the nuance your next clinic patient needs to hear.

Here are the key takeaways from this week in Urology. Sling and artificial sphincter both improve continence and satisfaction, but reoperation is substantially more likely after a sling. In irradiated bulbomembranous stenosis, anastomotic urethroplasty outperforms buccal graft onlay for durability with no added morbidity. Every curative prostate cancer treatment leaves most men with poor erectile function at one year, so counselling and rehabilitation should be proactive, not reactive. 5-alpha reductase inhibitors do not appear to raise male breast cancer risk, but do raise gynaecomastia and erectile dysfunction, more so with dutasteride. Holmium laser enucleation is the most cost-effective option across prostate sizes, though patient priorities around ejaculation can change that calculus. And an abnormal preoperative urinalysis may be the stronger infection signal, more so than an isolated positive culture.

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.